Author(s):
A. Swetha, K. Supraja, P. Jyothi, D.P. Krutal, G. Tulja Rani
Email(s):
swetha.addanki12@gmail.com
DOI:
10.52711/0974-360X.2025.00859 
Address:
A. Swetha1*, K. Supraja2, P. Jyothi3, D.P. Krutal4, G. Tulja Rani5
1Department of Pharmaceutical Analysis, Mallareddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad - 500100, Telangana, India.
2Department of Pharmacy, Mallareddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad - 500100, Telangana, India.
3Department of Pharmacy, Mallareddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad - 500100, Telangana, India.
4Department of Pharmacy, Mallareddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad - 500100, Telangana, India.
5Department of Pharmaceutical analysis, Mallareddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad - 500100, Telangana, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
The current technique sought to estimate Bexagliflozin by employing accurate, simple, specific, sensitive RP-HPLC procedure. Ascentis C18 [150mm×5.0mm,2.8µm particle size]column and mobile phase with ratio Methanol:(pH-4) 0.01N Potassium dihydrogen ortho phosphate [40:60 v/v]was used to design the present analytical RP-HPLC method with PDA detector of maximum wavelength 225nmat 1.2ml flow rate. Bexagliflozin was eluted at 2.857min retention time. The method linearity was evaluated at 5-30µg/ml concentration. The projected limit of quantification for bexagliflozin was 0.23µg/ml and the limit of detection for it was 0.08µg/ml. At 100.14%, Bexagliflozin achieved a range of percentage recovery. The results showed that Bexagliflozin had an intra-day precision of 0.7 and an inter-day precision of 0.8 %RSD. Studies were conducted in accordance with the guidelines set forth by the ICH. Bexagliflozin was estimated usingan accurate trouble shootingRP-HPLC method.
Cite this article:
A. Swetha, K. Supraja, P. Jyothi, D.P. Krutal, G. Tulja Rani. Novel Stability-Indicating RP-HPLC Method for Estimation of Bexagliflozin in Bulk and Pharmaceutical Dosage form. Research Journal Pharmacy and Technology. 2025;18(12):5942-8. doi: 10.52711/0974-360X.2025.00859
Cite(Electronic):
A. Swetha, K. Supraja, P. Jyothi, D.P. Krutal, G. Tulja Rani. Novel Stability-Indicating RP-HPLC Method for Estimation of Bexagliflozin in Bulk and Pharmaceutical Dosage form. Research Journal Pharmacy and Technology. 2025;18(12):5942-8. doi: 10.52711/0974-360X.2025.00859 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-49
REFERENCES:
1. Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, Trescoli C, Serusclat P, Freeman MW, Halvorsen YC. Safety and Effectiveness of Bexagliflozin in Patients with Type 2 Diabetes Mellitus and Stage 3a/3b CKD. American Journal of Kidney Diseases. 2019; 74(3): 328-37. doi: 10.1053/j.ajkd.2019.03.417.
2. Pasqualotto E, Figueiredo WJM, Gewehr DM, da Silva MR, van de SLS, de Araujo GN, Leal FS, Pinheiro CEA. Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obesity and Metabolism. 2023; 25(7): 1794-802. doi: 10.1111/dom.15051.
3. Omar A, Revathy C, Leslie MLG, Janis N, Vance B, Matthews, Markus PS. Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy. 2021: 22(16): 2095-103. doi:10.1080/14656566.2021.1959915
4. Shubham B, Prabhjeet KB, Manjusha C. Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egyptian Journal of Basic and Applied Sciences. 2023; 10(1): 69-82. doi:10.1080/2314808X.2022.2145734.
5. Jonali R, Harshil S, Vivek KV, Manmohan S. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I). European Journal of Medicinal Chemistry Reports. 2022; 6: 1-6. doi:10.1016/j.ejmcr.2022.100074
6. Andra F, Alana AH, ManuelOS, Laura AV, Sandra MF, Estefanía T, Esther RL, Manuel P, Oreste G, José Ramón GJ, Francisca L. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. International Journal of Molecular Sciences. 2022; 23(10): 5634-44. doi:10.3390/ijms23105634
7. Kaur I, Wakode S, Pal Singh H. Development and validation of stability indicating UV spectroscopic method for determination of canagliflozin in bulk and pharmaceutical dosage form. Pharm Methods. 2016; 7(1): 63–9. doi:10.5530/phm.2016.7.10
8. Haritha G, Aanandhi VM, Shanmugasundaram P. Novel Method Development for Metformin, Ivabradine, Metoprolol and Ertugliflozin and its Validation in API and Pharmaceutical Dosage Form by RPHPLC Method. Research Journal of Pharmacy and Technology. 2021; 14(4): 2055-1. doi: 10.52711/0974-360X.2021.00365
9. Deepthi R, Gowri Sankar D. A Novel UPLC Method for Simultaneous Estimation of Ertugliflozin and Sitagliptin in Bulk and Tablet Dosage Form. Research Journal of Pharmacy and Technology. 2021; 14(9): 4859-2. doi: 10.52711/0974-360X.2021.00844
10. Ghante MR, Tangade RB, Sawant SD, Kulkarni PD, Bhusari VK. Development and Validation of stability indicating RP-HPLC method for the estimation of Ertugliflozin by forced degradation studies. Research Journal of Pharmacy and Technology. 2022; 15(11): 4945-9. doi: 10.52711/0974-360X.2022.00831
11. Manojkumar KM, Kulkarni NS, Khiste RH, Dhanya BS. Development and Validation of Novel Analytical Method for Empagliflozin and Metformin Hydrochloride in Bulk and Pharmaceutical Dosage Form by Four Different Simultaneous Estimation Approaches using UV Spectroscopy. Research Journal of Pharmacy and Technology. 2020; 13(3): 1236-1242. doi: 10.5958/0974-360X.2020.00228.0
12. Manasa M, Vijey AM. Stability Indicating Simultaneous Method development and Validation of Dapagliflozin and Saxagliptin by RP-HPLC. Research Journal of Pharmacy and Technology. 2021; 14(2): 1045-1049. doi: 10.5958/0974-360X.2021.00187.6
13. Patel SB, Vaghasiya EH, Amit RD, Amitkumar JV, Ajay IP, Nilesh KP, Hina MJ. Stability Indicating Photodiode Array Detector Based Estimation of Dapagliflozin Propanediol Monohydrate in API and Tablet Dosage Form by RP-UPLC. Research Journal of Pharmacy and Technology. 2021; 14(9): 4635-9. doi: 10.52711/0974-360X.2021.00805
14. Nachiket SD, Ganesh SS, Vikas BS. Simultaneous Estimation and Validation of Canagliflozin and Metformin Hydrochloride in Bulk and Pharmaceutical Dosage Form by using RP-HPLC. Research J. Pharm. and Tech. 2019; 12(10): 4953-4957. doi: 10.5958/0974-360X.2019.00859.X
15. Vijaya SV, Choudhari VP, Venkata Reddy M. Development of new Validated HPTLC Method for simultaneous estimation of Canagliflozin and Metformin in Tablet Formulation. Research Journal of Pharmacy and Technology. 2022; 15(6): 2599-4. doi: 10.52711/0974-360X.2022.00434
16. Vidhi SD, Paresh UP. Development and Validation of Simultaneous Estimation of Canagliflozin and Metformin by Q Absorbance Ratio Method in its API and Tablet Formulation. Research Journal of Pharmacy and Technology. 2022; 15(10): 4637-0. doi: 10.52711/0974-360X.2022.00778
17. Rama KK, Sundararajan R. Stability Indicating and Simultaneous Determination of Saxagliptin, Dapagliflozin and Metformin in Tablet dosage form using RP-HPLC. Research Journal of Pharmacy and Technology. 2021; 14(11): 5813-8. doi: 10.52711/0974-360X.2021.01011
18. Ismail A, Mohammad H, Youssef Al. Estimation of Nine Organic Volatile Impurities in Bulk Dapagliflozin propandiol hydrate and Dosage forms from different sources using a new developed HS-GC-FID method. Research Journal of Pharmacy and Technology. 2022; 15(7): 3226-32. doi: 10.52711/0974-360X.2022.00541
19. Nihad KH, Abdulhakim N. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study. Research Journal of Pharmacy and Technology. 2023; 16(10): 4642-8. doi: 10.52711/0974-360X.2023.00755
20. Patel A. Method development for simultaneous estimation of dapagliflozin and saxagliptin in fixed-dose combination and validation on UV spectroscopic. Journal of Medical Pharmaceuticals Allied Sciences. 2020; 9(3): 2536–43. dooi: 10.22270/jmpas.v9i3.952
21. Siridevi MP, Kumar HT, Rao SY, Rao VPK. RP-HPLC method for quantification of empagliflozin in pharmaceutical formulation. Asian Journal Pharmacy Technology. 2019; 9(3): 208. doi:10.5958/2231-5713.2019.00035.7
22. Pathak S, Mishra P. Stability-indicating HPLC-DAD method for the determination of empagliflozin. Future Journal Pharmaceutical Sciences. 2021; 7(1). doi: 10.1186/s43094-021-00329-w
23. Vankalapati KR, Alegete P, Boodida S. Stability-indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form. Biomedical Chromatography. 2022; 36(7): e5384. doi:10.1002/bmc.5384
24. Nandre DS, Ahmed A. Stability indicating hplc method development and validation for simultaneous estimation of dapagliflozin and metformin tablet dosage form. Asian Journal Pharmaceutical and Clinical Research. 2022; 109–14. doi: 10.22159/ajpcr.2022.v15i10.45616
25. Gaikwad AV, Khulbe P. HPLC method development for the estimation of Empagliflozin in bulk and pharmaceutical formulation. Journal of Pharmaceutical Research International. 2022; 22–31. doi:10.9734/jpri/2022/v34i23b35926
26. M Hanif, Bushra R, Ismail NE, Bano R, Abedin S, Alam S. Empagliflozin: HPLC based analytical method development and application to pharmaceutical raw material and dosage form. Pakistan Journal Pharmaceutical Sciences. 2021; 34(3): 1081-7. doi:10.36721/PJPS.2021.34.3
27. Dayyih WA, Ani IA, Al-Shdefat RI, Zakareia Z, Hamid SA, Shakya AK. Development and validation of a stability indicating HPLC method for empagliflozin and linagliptin in tablet dosage form. Asian Journal of Chemistry. 2021; 33(2): 484–8. doi:10.14233/ajchem.2021.23019
28. L.B. Borse, M.S. Wagh, S.L. Borse, S.P. Ahire, I.S. Vaishnav, V.D. Naphade, et al. RP- HPLC method development and validation for estimation of dapagliflozin in tablet formulation. Journal of Pharmaceutical Negative Results. 2022; 364–72. doi:10.47750/pnr.2022.13.s05.53
29. Dhale CR, Rao. Stability indicating hplc method development and validation for the simultaneous estimation of metformin hydrochloride and dapagliflozin in api and pharmaceutical dosage form. International Research Journal Pharmacy. 2021; 12(8): 52–7. doi:10.7897/2230-8407.1208157
30. Verma MV, Patel CJ, Patel MM. Development and stability indicating hplc method for dapagliflozin in api and pharmaceutical dosage form. International Journal of Applied Pharmaceutics. 2017; 9(5): 33. doi:10.22159/ijap.2017v9i5.19185
31. Bhatt D, Thatavarthi P, Rajkamal B. Analytical method development and validation for the estimation of Canagliflozin in bulk and formulation by RP- HPLC. Intternational Journal of Pharmaceutical Research. 2018; 10(03). doi:10.25004/ijpsdr.2018.100306
32. Al-Shdefat R, Al-Ani I, Tamimi L, Awad R, Rayyan WA, Dayyih WA. Development and validation of a stability-indicating HPLC-DAD method for the determination of canagliflozin and metformin simultaneously in combination dosage form. Pharmaceutical Chemistry Journal. 2021; 55(4): 402–9. doi: 10.1007/s11094-021-02436-7
33. Moktar MM, Sujan MS, Heba MEA, Fotouh RM. A UPLC/DAD method for simultaneous determination of empagliflozin and three related substances in spiked human plasma. BMC Chemistry. July 2019; 13(1): 83-95. doi: 10.1186/s13065-019-0604-9
34. Asmaa A, El-Zaher, Hanaa AH, Ehab FE, Marwa AA. A validated LC-MS/MS bioanalytical method for the simultaneous determination of dapagliflozin or saxagliptin with metformin in human plasma. Microchemical Journal. 2019; 149: 1-10. doi: 10.1016/j.microc.2019.104017.
35. Ramya KB, Swetha A. Novel stability indicating RP-UPLC method for silmultaneous estimation of sitagliptin and ertugliflozin in bulk and pharmaceutical formulations. Future Journal of Pharmaceutical Sciences. 2021; 7: 86. doi: https://doi.org/10.1186/s43094-021-00231-5
36. ICH Harmonized Tripartite (2005), Validation of analytical procedures: text and methodology Q2 (R1). International Conference on Harmonization, Geneva Available from: http://www.ich.org/fileadmin/public_web_site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf. (Accessed 12 Mar 2020)
37. ICH Harmonized Tripartite, Stability testing of new drug substance and products Q1A(R2), 2003. International Conference on Harmonization, Geneva Available from: http://www.ich.org/fileadmin/public_web_site/ICH_Products/Guidelines/Quality/Q1A_R2_Guideline.pdf. (Accessed12 Mar 2020)